Top Markets
Coin of the day
DermTech, Inc. DermTech, Inc.

DermTech, Inc.

DMTK
株式のランク #37065
DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla,... DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla, California, specializes in creating and bringing to market advanced, non-invasive genomic tests. Operating within the United States, their innovative solutions facilitate the diagnosis of various dermatological issues, including skin cancer, inflammatory conditions, and age-related skin concerns. A cornerstone of their offerings is the DermTech Melanoma Test (DMT), a sophisticated gene expression analysis. This assay plays a crucial role in enhancing the early identification of genomic abnormalities, effectively aiding in the exclusion of melanoma and often removing the need for invasive surgical biopsies of suspicious pigmented lesions. The company further provides specialized adhesive kits for convenient skin sample collection. Additionally, they offer gene expression assays designed to analyze key inflammatory pathways such, as Th1, Th2, IFN-gamma, and Th17. Looking ahead, DermTech is actively developing a pipeline of new products, which includes DNA risk assessment tools for UV damage, diagnostic tests for non-melanoma skin cancers, and rule-out tests for cutaneous T-cell lymphoma. They also extend their services by delivering health-related information and support through digital and telecommunication platforms. DermTech's diagnostic products and services are primarily targeted towards medical professionals in the fields of pathology and oncology.
株価
$0.069
最終同期: 2024-07-22
時価総額
$2.06M
変化(1日)
-1.43%
変化(1年)
0.00%
US
取引 DermTech, Inc. (DMTK)

カテゴリー

DermTech, Inc.(DMTK)のP/E比率
August 2026 時点のP/E比率 TTM -0.03
DermTech, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -0.03 です。2022 年末時点での P/E は -0.46 でした。
DermTech, Inc. の P/E 比率の履歴(2016 〜 2026)
各年末のP/E比率
P/E比率 変化
2026 (TTM) -0.03 -94.37%
2023 -0.54 17.86%
2022 -0.46 -92.18%
2021 -5.83 -61.42%
2020 -15.10 249.93%
2019 -4.32 -102.06%
2018 209.29 -100.01%
2017 -3.00M 4,455.00%
2016 -65.77K 0.00%
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差
31.59 -104,029.28%
US
35.83 -117,968.09%
US
- -
CN
-227.89 749,537.17%
US
38.69 -127,373.03%
US
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。